Search Results

You are looking at 71 - 80 of 131 items for :

  • Abstract: Calcium x
  • Abstract: Hypoparathyroidism x
  • Abstract: Menopause x
  • Abstract: Vitamin D x
Clear All Modify Search
Iulia Soare University of Medicine and Pharmacy ‘Carol Davila’ Bucharest, Bucharest, Romania

Search for other papers by Iulia Soare in
Google Scholar
PubMed
Close
,
Anca Sirbu University of Medicine and Pharmacy ‘Carol Davila’ Bucharest, Bucharest, Romania
Department of Endocrinology, Diabetes and Metabolic diseases, Elias Hospital, Bucharest, Romania

Search for other papers by Anca Sirbu in
Google Scholar
PubMed
Close
,
Mihai Mircea Diculescu University of Medicine and Pharmacy ‘Carol Davila’ Bucharest, Bucharest, Romania
Department of Gastroenterology, Fundeni Clinical Institute, Bucharest, Romania

Search for other papers by Mihai Mircea Diculescu in
Google Scholar
PubMed
Close
,
Bogdan Radu Mateescu University of Medicine and Pharmacy ‘Carol Davila’ Bucharest, Bucharest, Romania
Department of Gastroenterology, Colentina Hospital, Bucharest, Romania

Search for other papers by Bogdan Radu Mateescu in
Google Scholar
PubMed
Close
,
Cristian Tieranu University of Medicine and Pharmacy ‘Carol Davila’ Bucharest, Bucharest, Romania
Department of Gastroenterology, Elias Hospital, Bucharest, Romania

Search for other papers by Cristian Tieranu in
Google Scholar
PubMed
Close
,
Sorina Martin University of Medicine and Pharmacy ‘Carol Davila’ Bucharest, Bucharest, Romania
Department of Endocrinology, Diabetes and Metabolic diseases, Elias Hospital, Bucharest, Romania

Search for other papers by Sorina Martin in
Google Scholar
PubMed
Close
,
Carmen Gabriela Barbu University of Medicine and Pharmacy ‘Carol Davila’ Bucharest, Bucharest, Romania
Department of Endocrinology, Diabetes and Metabolic diseases, Elias Hospital, Bucharest, Romania

Search for other papers by Carmen Gabriela Barbu in
Google Scholar
PubMed
Close
,
Mirela Ionescu University of Medicine and Pharmacy ‘Carol Davila’ Bucharest, Bucharest, Romania
Department of Gastroenterology, Elias Hospital, Bucharest, Romania

Search for other papers by Mirela Ionescu in
Google Scholar
PubMed
Close
, and
Simona Fica University of Medicine and Pharmacy ‘Carol Davila’ Bucharest, Bucharest, Romania
Department of Endocrinology, Diabetes and Metabolic diseases, Elias Hospital, Bucharest, Romania

Search for other papers by Simona Fica in
Google Scholar
PubMed
Close

Background and aim

Low bone mineral density (BMD) is a common complication in patients with inflammatory bowel disease (IBD). However, debates are ongoing with regard to the other involved factors, especially in younger patients. This study aimed to evaluate the parameters that contribute to decreased BMD, focusing on premenopausal women and men aged <50 years.

Methods

This study included 81 patients with IBD and 81 age-, sex- and BMI-matched controls. Blood tests were conducted on IBD patients, and a dual-energy X-ray absorptiometry (DXA) scan was performed on both groups.

Results

Low BMD and fragility fracture were found to be more prevalent in IBD patients than in healthy subjects (49.3% vs 23.4%, P = 0.001 and 9.8% vs 1.2%, P = 0.01, respectively). Patients with low BMD were older, with a longer disease duration, higher faecal calprotectin (FC) levels and lower magnesium and lean mass (appreciated as appendicular skeletal muscle index (ASMI)). Multiple regression analysis revealed that ASMI, age and use of glucocorticoids were the independent parameters for decreased BMD. Although 91.3% of the patients had a 25-hydroxy vitamin D level of <30 ng/mL, it was not a statistically significant factor for decreased BMD.

Conclusion

In our study, the levels of vitamin D did not seem to have an important impact on BMD. Conversely, FC, magnesium and lean mass are important factors, suggesting that good control of disease, adequate magnesium intake and increased lean mass can have a good impact on bone metabolism in patients with IBD.

Open access
Alexander V Amram Department of Physiology, Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California, USA
Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, California, USA

Search for other papers by Alexander V Amram in
Google Scholar
PubMed
Close
,
Stephen Cutie Department of Physiology, Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California, USA
Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, California, USA

Search for other papers by Stephen Cutie in
Google Scholar
PubMed
Close
, and
Guo N Huang Department of Physiology, Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California, USA
Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, University of California, San Francisco, San Francisco, California, USA

Search for other papers by Guo N Huang in
Google Scholar
PubMed
Close

Research conducted across phylogeny on cardiac regenerative responses following heart injury implicates endocrine signaling as a pivotal regulator of both cardiomyocyte proliferation and heart regeneration. Three prominently studied endocrine factors are thyroid hormone, vitamin D, and glucocorticoids, which canonically regulate gene expression through their respective nuclear receptors thyroid hormone receptor, vitamin D receptor, and glucocorticoid receptor. The main animal model systems of interest include humans, mice, and zebrafish, which vary in cardiac regenerative responses possibly due to the differential onsets and intensities of endocrine signaling levels throughout their embryonic to postnatal organismal development. Zebrafish and lower vertebrates tend to retain robust cardiac regenerative capacity into adulthood while mice and other higher vertebrates experience greatly diminished cardiac regenerative potential in their initial postnatal period that is sustained throughout adulthood. Here, we review recent progress in understanding how these three endocrine signaling pathways regulate cardiomyocyte proliferation and heart regeneration with a particular focus on the controversial findings that may arise from different assays, cellular-context, age, and species. Further investigating the role of each endocrine nuclear receptor in cardiac regeneration from an evolutionary perspective enables comparative studies between species in hopes of extrapolating the findings to novel therapies for human cardiovascular disease.

Open access
Raja Padidela Royal Manchester Children’s Hospital and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

Search for other papers by Raja Padidela in
Google Scholar
PubMed
Close
,
Moira S Cheung Evelina London Children’s Hospital, London, UK

Search for other papers by Moira S Cheung in
Google Scholar
PubMed
Close
,
Vrinda Saraff Birmingham Women’s and Children’s Hospital, Birmingham, UK

Search for other papers by Vrinda Saraff in
Google Scholar
PubMed
Close
, and
Poonam Dharmaraj Alder Hey Children’s NHS Foundation Trust, Liverpool, UK

Search for other papers by Poonam Dharmaraj in
Google Scholar
PubMed
Close

X-linked hypophosphataemia (XLH) is caused by a pathogenic variant in the PHEX gene, which leads to elevated circulating FGF23. High FGF23 causes hypophosphataemia, reduced active vitamin D concentration and clinically manifests as rickets in children and osteomalacia in children and adults. Conventional therapy for XLH includes oral phosphate and active vitamin D analogues but does not specifically treat the underlying pathophysiology of elevated FGF23-induced hypophosphataemia. In addition, adherence to conventional therapy is limited by frequent daily dosing and side effects such as gastrointestinal symptoms, secondary hyperparathyroidism and nephrocalcinosis. Burosumab, a recombinant human IgG1 MAB that binds to and inhibits the activity of FGF23, is administered subcutaneously every 2 weeks. In clinical trials (phase 2 and 3) burosumab was shown to improve phosphate homeostasis that consequently resolves the skeletal/non-skeletal manifestations of XLH. Burosumab was licensed in Europe (February 2018) with the National Institute for Health and Care Excellence, UK approving use within its marketing authorisation in October 2018. In this publication, the British Paediatric and Adolescent Bone Group (BPABG) reviewed current evidence and provide expert recommendations for care pathway and management of XLH with burosumab.

Open access
Søs Dragsbæk Larsen Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

Search for other papers by Søs Dragsbæk Larsen in
Google Scholar
PubMed
Close
,
Christine Dalgård Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Department of Public Health, Environmental Medicine, University of Southern Denmark, Odense, Denmark

Search for other papers by Christine Dalgård in
Google Scholar
PubMed
Close
,
Mathilde Egelund Christensen Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

Search for other papers by Mathilde Egelund Christensen in
Google Scholar
PubMed
Close
,
Sine Lykkedegn Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark

Search for other papers by Sine Lykkedegn in
Google Scholar
PubMed
Close
,
Louise Bjørkholt Andersen Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Department of Obstetrics and Gynecology, Herlev Hospital, Copenhagen, Denmark

Search for other papers by Louise Bjørkholt Andersen in
Google Scholar
PubMed
Close
,
Marianne Andersen Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Department of Medical Endocrinology, Odense University Hospital, Odense, Denmark

Search for other papers by Marianne Andersen in
Google Scholar
PubMed
Close
,
Dorte Glintborg Department of Medical Endocrinology, Odense University Hospital, Odense, Denmark

Search for other papers by Dorte Glintborg in
Google Scholar
PubMed
Close
, and
Henrik Thybo Christesen Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark

Search for other papers by Henrik Thybo Christesen in
Google Scholar
PubMed
Close

Background

Low foetal vitamin D status may be associated with higher blood pressure (BP) in later life.

Objective

To examine whether serum 25-hydroxyvitamin D2+3 (s-25OHD) in cord and pregnancy associates with systolic and diastolic BP (SBP; DBP) in children up to 3 years of age.

Design

Prospective, population-based cohort study.

Methods

We included 1594 singletons from the Odense Child Cohort with available cord s-25OHD and BP data at median age 3.7 months (48% girls), 18.9 months (44% girls) or 3 years (48% girls). Maternal s-25OHD was also assessed at gestational ages 12 and 29 weeks. Multiple regression models were stratified by sex a priori and adjusted for maternal educational level, season of birth and child height, weight and age.

Results

In 3-year-old girls, SBP decreased with −0.7 mmHg (95% CI −1.1; −0.3, P = 0.001) and DBP with −0.4 mmHg (95% CI −0.7; −0.1, P = 0.016) for every 10 nmol/L increase in cord s-25OHD in adjusted analyses. Moreover, the adjusted odds of having SBP >90th percentile were reduced by 30% for every 10 nmol/L increase in cord s-25OHD (P = 0.004) and by 64% for cord s-25OHD above the median 45.1 nmol/L (P = 0.02). Similar findings were observed between pregnancy s-25OHD and 3-year SBP, cord s-25OHD and SBP at 18.9 months, and cord s-25OHD and DBP at 3 years. No consistent associations were observed between s-25OHD and BP in boys.

Conclusion

Cord s-25OHD was inversely associated with SBP and DBP in young girls, but not in boys. Higher vitamin D status in foetal life may modulate BP in young girls. The sex difference remains unexplained.

Open access
Fabienne A U Fox Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

Search for other papers by Fabienne A U Fox in
Google Scholar
PubMed
Close
,
Lennart Koch Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
University for Health Sciences, Medical Informatics and Technology (UMIT TIROL), Tirol, Austria

Search for other papers by Lennart Koch in
Google Scholar
PubMed
Close
,
Monique M B Breteler Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Faculty of Medicine, University of Bonn, Bonn, Germany

Search for other papers by Monique M B Breteler in
Google Scholar
PubMed
Close
, and
N Ahmad Aziz Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Department of Neurology, Faculty of Medicine, University of Bonn, Bonn, Germany

Search for other papers by N Ahmad Aziz in
Google Scholar
PubMed
Close

Objective

Maintaining muscle function throughout life is critical for healthy ageing. Although in vitro studies consistently indicate beneficial effects of 25-hydroxyvitamin D (25-OHD) on muscle function, findings from population-based studies remain inconclusive. We therefore aimed to examine the association between 25-OHD concentration and handgrip strength across a wide age range and assess potential modifying effects of age, sex and season.

Methods

We analysed cross-sectional baseline data of 2576 eligible participants out of the first 3000 participants (recruited from March 2016 to March 2019) of the Rhineland Study, a community-based cohort study in Bonn, Germany. Multivariate linear regression models were used to assess the relation between 25-OHD levels and grip strength while adjusting for age, sex, education, smoking, season, body mass index, physical activity levels, osteoporosis and vitamin D supplementation.

Results

Compared to participants with deficient 25-OHD levels (<30 nmol/L), grip strength was higher in those with inadequate (30 to <50 nmol/L) and adequate (≥50 to ≤125 nmol/L) levels (ß inadequate = 1.222, 95% CI: 0.377; 2.067, P = 0.005; ß adequate = 1.228, 95% CI: 0.437; 2.019, P = 0.002). Modelling on a continuous scale revealed grip strength to increase with higher 25-OHD levels up to ~100 nmol/L, after which the direction reversed (ß linear = 0.505, 95% CI: 0.179; 0.830, P = 0.002; ß quadratic = –0.153, 95% CI: –0.269; -0.038, P = 0.009). Older adults showed weaker effects of 25-OHD levels on grip strength than younger adults (ß 25OHDxAge = –0.309, 95% CI: –0.594; –0.024, P = 0.033).

Conclusions

Our findings highlight the importance of sufficient 25-OHD levels for optimal muscle function across the adult life span. However, vitamin D supplementation should be closely monitored to avoid detrimental effects.

Open access
Rong Xu Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Rong Xu in
Google Scholar
PubMed
Close
,
Difei Lian Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Difei Lian in
Google Scholar
PubMed
Close
,
Yan Xie Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Yan Xie in
Google Scholar
PubMed
Close
,
Lin Mu Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Lin Mu in
Google Scholar
PubMed
Close
,
Yali Wu Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Yali Wu in
Google Scholar
PubMed
Close
,
Zhilei Chen Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Zhilei Chen in
Google Scholar
PubMed
Close
, and
Baoyu Zhang Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Baoyu Zhang in
Google Scholar
PubMed
Close

Osteoporosis (OP) is a systemic bone disease in which bone density and quality decrease and bone fragility increases due to a variety of causes, making it prone to fractures. The development of OP is closely related to oxidative stress. Uric acid (UA) is the end product of purine metabolism in the human body. Extracellular UA has antioxidant properties and is thought to have a protective effect on bone metabolism. However, the process of UA degradation can lead to intracellular oxidative stress, which together with UA-induced inflammatory factors, leads to increased bone destruction. In addition, UA can inhibit vitamin D production, resulting in secondary hyperparathyroidism and further exacerbating UA-associated bone loss. This review summarizes the relationship between serum UA levels and bone mineral density, bone turnover markers, and so on, in the hope of providing new insights into the pathogenesis and treatment of OP.

Open access
Elena Valassi Endocrinology/Medicine Department, Hospital Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), IIB-Sant Pau, ISCIII and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

Search for other papers by Elena Valassi in
Google Scholar
PubMed
Close
,
Natalia García-Giralt URFOA, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Universitat Autònoma de Barcelona, Barcelona, Spain

Search for other papers by Natalia García-Giralt in
Google Scholar
PubMed
Close
,
Jorge Malouf Mineral Metabolism Unit, Medicine Department, Hospital Sant Pau, Barcelona, Spain

Search for other papers by Jorge Malouf in
Google Scholar
PubMed
Close
,
Iris Crespo Endocrinology/Medicine Department, Hospital Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), IIB-Sant Pau, ISCIII and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

Search for other papers by Iris Crespo in
Google Scholar
PubMed
Close
,
Jaume Llauger Radiology Department, Hospital Sant Pau, Barcelona, Spain

Search for other papers by Jaume Llauger in
Google Scholar
PubMed
Close
,
Adolfo Díez-Pérez URFOA, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Universitat Autònoma de Barcelona, Barcelona, Spain

Search for other papers by Adolfo Díez-Pérez in
Google Scholar
PubMed
Close
, and
Susan M Webb Endocrinology/Medicine Department, Hospital Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), IIB-Sant Pau, ISCIII and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

Search for other papers by Susan M Webb in
Google Scholar
PubMed
Close

Background

Biochemical control of GH/IGF-I excess in acromegaly (ACRO) is associated with persistent impairment of trabecular microstructure leading to increased risk of vertebral fractures. Circulating miRNAs modulate the activity of osteoblasts and osteoclasts, and may be potential biomarkers of osteoporosis.

Aims

Identify differentially expressed miRNAs in the serum of patients with controlled ACRO vs controls and correlate miRNA levels with both biochemical and structural bone parameters.

Patients and methods

Twenty-seven patients with controlled ACRO (11 males, 16 females; mean age, 48 ± 5 years; BMI, 28 ± 4 kg/m2) and 27 age-, gender- and BMI-matched controls were recruited. Areal BMD at lumbar spine and femur, and trabecular bone score were assessed; volumetric BMD was measured by quantitative computed tomography QCT-Pro (Mindways). Twenty miRNAs, chosen by their putative role in bone, were quantified in serum using real-time qPCR.

Results

In ACRO patients, miR-103a-3p and miR-191-5p were found overexpressed, whereas miR-660-5p was underexpressed (P < 0.001). miR-103a-3p levels were negatively associated with both trabecular vBMD at trochanter and serum osteoprotegerin concentrations (P < 0.05) and positively with vitamin D concentrations (P < 0.01) and total cross-sectional area of the femoral neck (P < 0.05). miR-660-5p levels were correlated with both trabecular vBMD at trochanter and OPG concentrations (P < 0.05), but were negatively associated with vitamin D levels (P < 0.05). A negative correlation between miR-103-a-3p and miR-660-5p was found in both groups (P < 0.001).

Conclusions

Circulating miR-103a-3p and miR-660-5p are differentially expressed in controlled ACRO patients and associated with bone structural parameters. miRNAs may be one of the mechanisms involved in the pathogenesis of bone disease and could be used as biomarkers in ACRO patients.

Open access
A Gizard Department of Pediatric Orthopedic Surgery, Besançon University Hospital, Paris, France

Search for other papers by A Gizard in
Google Scholar
PubMed
Close
,
A Rothenbuhler APHP, Department of Pediatric Endocrinology, Bicêtre Paris Sud, Le Kremlin Bicêtre, France
Reference Center for Rare Disorders of Calcium and Phosphate Metabolism, Le Kremlin Bicêtre, France
Plateforme d’Expertise Paris Sud Maladies Rares and Filière OSCAR, Bicêtre Paris Sud, Le Kremlin Bicêtre, France

Search for other papers by A Rothenbuhler in
Google Scholar
PubMed
Close
,
Z Pejin APHP, Department of Pediatric Orthopedic Surgery, Necker Hospital, Paris, France

Search for other papers by Z Pejin in
Google Scholar
PubMed
Close
,
G Finidori APHP, Department of Pediatric Orthopedic Surgery, Necker Hospital, Paris, France

Search for other papers by G Finidori in
Google Scholar
PubMed
Close
,
C Glorion APHP, Department of Pediatric Orthopedic Surgery, Necker Hospital, Paris, France

Search for other papers by C Glorion in
Google Scholar
PubMed
Close
,
B de Billy Department of Pediatric Orthopedic Surgery, Besançon University Hospital, Paris, France

Search for other papers by B de Billy in
Google Scholar
PubMed
Close
,
A Linglart APHP, Department of Pediatric Endocrinology, Bicêtre Paris Sud, Le Kremlin Bicêtre, France
Reference Center for Rare Disorders of Calcium and Phosphate Metabolism, Le Kremlin Bicêtre, France
Plateforme d’Expertise Paris Sud Maladies Rares and Filière OSCAR, Bicêtre Paris Sud, Le Kremlin Bicêtre, France
INSERM U1169, Hôpital Bicêtre, Le Kremlin Bicêtre, et Université Paris-Saclay, Le Kremlin Bicêtre, France

Search for other papers by A Linglart in
Google Scholar
PubMed
Close
, and
P Wicart Reference Center for Rare Disorders of Calcium and Phosphate Metabolism, Le Kremlin Bicêtre, France
APHP, Department of Pediatric Orthopedic Surgery, Necker Hospital, Paris, France

Search for other papers by P Wicart in
Google Scholar
PubMed
Close

Background

X-linked hypophosphatemic rickets (XLHR) is due to mutations in PHEX leading to unregulated production of FGF23 and hypophosphatemia. XLHR is characterized by leg bowing of variable severity. Phosphate supplements and oral vitamin analogs, partially or, in some cases, fully restore the limb straightness. Surgery is the alternative for severe or residual limb deformities.

Objective

To retrospectively assess the results of surgical limb correction in XLHR (osteotomies and bone alignment except for 3 transient hemiepiphysiodesis).

Methods

We analyzed the incidence of recurrence and post-surgical complications in 49 XLHR patients (29F, 20M) (mean age at diagnosis 6.0 years (± 7.1)).

Results

At first surgery, the mean age was 13.4 years (± 5.0). Recurrence was observed in 14/49 (29%) patients. The number of additional operations significantly decreased with age (2.0 (± 0.9), 1.7 (± 1.0) and 1.2 (± 0.4) in children <11 years, between 11 and 15, and >15 years; P < 0.001). Incidence of recurrence seemed to be lower in patients with good metabolic control of the rickets (25% vs 33%). Complications were observed in 57% of patients.

Conclusion

We report a large series of surgical procedures in XLHR. Our results confirm that phosphate supplements and vitamin D analog therapy is the first line of treatment to correct leg bowing. Surgery before puberty is associated with a high risk of recurrence of the limb deformity. Such procedures should only be recommended, following multidisciplinary discussions, in patients with severe distortion leading to mechanical joint and ligament complications, or for residual deformities once growth plates have fused.

Open access
Ozlem Atan Sahin Department of Pediatrics, Acıbadem University School of Medicine, Atasehir, Istanbul, Turkey

Search for other papers by Ozlem Atan Sahin in
Google Scholar
PubMed
Close
,
Damla Goksen Department of Pediatric Endocrinology, Faculty of Medicine, Ege University, Bornova, Izmir, Turkey

Search for other papers by Damla Goksen in
Google Scholar
PubMed
Close
,
Aysel Ozpinar Department of Biochemistry, Acıbadem University, School of Medicine, Atasehir, Istanbul, Turkey

Search for other papers by Aysel Ozpinar in
Google Scholar
PubMed
Close
,
Muhittin Serdar Department of Biochemistry, Acıbadem University, School of Medicine, Atasehir, Istanbul, Turkey

Search for other papers by Muhittin Serdar in
Google Scholar
PubMed
Close
, and
Huseyin Onay Department of Medical Genetics, Faculty of Medicine, Ege University, Bornova, Izmir, Turkey

Search for other papers by Huseyin Onay in
Google Scholar
PubMed
Close

Background

There have been studies focused on FokI, BsmI, ApaI and TaqI polymorphisms of the vitamin D receptor (VDR) gene and susceptibility to type 1 diabetes mellitus with controversial results.

Methods

This present study is a meta-analysis investigating the association between FokI, ApaI, TaqI and BsmI polymorphisms of VDR gene and type 1 DM in children. A literature search was performed using Medline, EMBASE, Cochrane and PubMed. Any study was considered eligible for inclusion if at least one of FokI, ApaI, TaqI and BsmI polymorphisms was determined, and outcome was type 1 DM at pediatric age.

Results

A total of 9 studies comprising 1053 patients and 1017 controls met the study inclusion criteria. The pooled odds ratios (ORs) of the FokI, ApaI, TaqI and BsmI polymorphisms were combined and calculated. Forest plots and funnel plots of the OR value distributions were drawn. Our meta-analysis has demonstrated statistically significant associations between DM1 and VDR genotypes, BsmIBB (P < 0.05), BsmIBb, (P < 0.05), BsmIbb (P < 0.05), TaqITT (P < 0.05) and TaqItt (P < 0.05) in children.

Conclusion

The results indicated that BsmIBB, BsmIBb and TaqItt polymorphisms were associated with an increased risk of type 1 DM, whereas BsmIbb and TaqITT had protective effect for type 1 DM in children.

Open access
June Young Choi Department of Surgery, Seoul National University Bundang Hospital, Seongnam-si, Korea

Search for other papers by June Young Choi in
Google Scholar
PubMed
Close
,
Jin Wook Yi Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Korea

Search for other papers by Jin Wook Yi in
Google Scholar
PubMed
Close
,
Jun Hyup Lee Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Korea

Search for other papers by Jun Hyup Lee in
Google Scholar
PubMed
Close
,
Ra-Yeong Song Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Korea

Search for other papers by Ra-Yeong Song in
Google Scholar
PubMed
Close
,
Hyeongwon Yu Department of Surgery, Seoul National University Bundang Hospital, Seongnam-si, Korea

Search for other papers by Hyeongwon Yu in
Google Scholar
PubMed
Close
,
Hyungju Kwon Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Korea

Search for other papers by Hyungju Kwon in
Google Scholar
PubMed
Close
,
Young Jun Chai Department of Surgery, Seoul National University Boramae Hospital, Seoul, Korea

Search for other papers by Young Jun Chai in
Google Scholar
PubMed
Close
,
Su-jin Kim Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Korea

Search for other papers by Su-jin Kim in
Google Scholar
PubMed
Close
, and
Kyu Eun Lee Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Korea

Search for other papers by Kyu Eun Lee in
Google Scholar
PubMed
Close

The purpose of this study was to assess the relationship between vitamin D receptor gene (VDR) expression and prognostic factors in papillary thyroid cancer (PTC). mRNA sequencing and somatic mutation data from The Cancer Genome Atlas (TCGA) were analyzed. VDR mRNA expression was compared to clinicopathologic variables by linear regression. Tree-based classification was applied to find cutoff and patients were split into low and high VDR group. Logistic regression, Kaplan–Meier analysis, differentially expressed gene (DEG) test and pathway analysis were performed to assess the differences between two VDR groups. VDR mRNA expression was elevated in PTC than that in normal thyroid tissue. VDR expressions were high in classic and tall-cell variant PTC and lateral neck node metastasis was present. High VDR group was also associated with classic and tall cell subtype, AJCC stage IV and lower recurrence-free survival. DEG test reveals that 545 genes were upregulated in high VDR group. Thyroid cancer-related pathways were enriched in high VDR group in pathway analyses. VDR mRNA overexpression was correlated with worse prognostic factors such as subtypes of papillary thyroid carcinoma that are known to be worse prognosis, lateral neck node metastasis, advanced stage and recurrence-free survival.

Open access